Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Liabilities: 2010-2025

Historic Total Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $881.9 million.

  • Arrowhead Pharmaceuticals' Total Liabilities fell 7.05% to $881.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $881.9 million, marking a year-over-year decrease of 7.05%. This contributed to the annual value of $881.9 million for FY2025, which is 7.05% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Total Liabilities stood at $881.9 million for FY2025, which was down 7.05% from $948.7 million recorded in FY2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Total Liabilities peaked at $948.7 million during FY2024, and registered a low of $273.6 million during FY2022.
  • Moreover, its 3-year median value for Total Liabilities was $881.9 million (2025), whereas its average is $769.7 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 396.21% in 2021, then fell by 9.20% in 2022.
  • Arrowhead Pharmaceuticals' Total Liabilities (Yearly) stood at $301.3 million in 2021, then dropped by 9.20% to $273.6 million in 2022, then surged by 74.85% to $478.4 million in 2023, then surged by 98.32% to $948.7 million in 2024, then fell by 7.05% to $881.9 million in 2025.